Fatigue / dizziness Diarrhoea, especially when paired with reduced appetite, can lead to dehydration, which can cause dizziness or unexpected tiredness
The GLP-1 receptor agonist semaglutide reduces risks of kidney function loss, kidney failure, cardiovascular events, cardiovascular death and all-cause mortality in people with CKD and T2DM Ongoing clinical and mechanistic studies are expected to expand use of GLP-1 receptor agonists, GLP-1/GIP and other metabolic hormones for the treatment of CKD At the moment the most complete data is available for semaglutide from SUSTAIN-6 and FLOW trial which is the only trial with primary renal outcome in T2DM patients out of all GLP-1 RA Very good data for renal outcomes as secondary ones available for GLP-1 RAs dulaglutide and liraglutide and GLP-1/GIP RA tirzepatide, Very interesting and positive data from mechanistic REMODEL trial with semaglutide in T2DM patients presented but not yet published (reduced perirenal fat, rernal fibrosis and much more) Based on following excellent papers: #glp1 #gip #semaglutide #tirzepatide #liraglutide #dulaglutide #kidney #ckd #chronickidneydisease #cardiovascularcomplications Martin Haluzks Post -1 Incretins have an important role in glucose homeostasis, regulation of appetite, energy expenditure and immunity
Europe Glutathione Market Challenges 3.2.3
5 Conclusions The absence of any effects of hepatic impairment on the PK of tirzepatide would suggest that a dose adjustment of tirzepatide, based on PK parameters, may not be required in people with hepatic impairment
Whilst erectile dysfunction is a significant concern for many men with diabetes, current clinical evidence does not establish a direct link between Mounjaro and impotence
&srotate=0)
